Abstract:Objective: To explore the effect of hyperlipidemia on the sensitivity of regular uric acid lowering therapy in patients with primary gout. Methods: The clinical data of 120 gout patients treated with regular uric acid lowering therapy in the Department of Rheumatology and immunology of the tirsa affiliated hospital of Hainan Medical College from April 2020 to June 2021 were analyzed retrospectively. According to the treatment sensitivity, they were divided into sensitive group (78 cases) and drug-resistant group (42 cases). Gender, age, course of disease, family history of gout, baseline value of serum uric acid and blood lipid indexes triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) other relevant data were collected and compared between the two groups. The incidence of hyperlipidemia in the two groups was counted, The internal relationship between hyperlipidemia and the sensitivity of regular uric acid lowering therapy was analyzed. Results: The course of disease, combined with gout stone, frequency of gout attack, history of hypertension, baseline value of serum uric acid and serum creatinine (SCR) level in the drug-resistant group were significantly higher than those in the sensitive group (P< 0.05).The incidence of serum TG (1.68 ± 0.40) mmol / L and hyperlipidemia in the drug-resistant group was 38.10% higher than that in the sensitive group (1.54 ± 0.31) mmol / L and 12.82%, and HDL-C (1.06 ± 0.27) mmol / l was lower than that in the sensitive group (1.21 ± 0.23) mmol / L, the difference was statistically significant (P< 0.05). Multivariate logistic regression analysis showed that the course of disease (OR= 1.308, 95% CI:), higher baseline value of serum uric acid (OR= 2.017, 95% CI: 1.426 ~ 2.608), gout stone (OR = 1.208, 95% CI: 1.031 ~ 1.385), history of hypertension (OR= 1.250, 95% CI: 1.071 ~ 1.429), and hyperlipidemia (OR= 1.529, 95% CI: 1.138 ~ 1.920) were independent influencing factors of poor sensitivity of regular uric acid lowering therapy in patients with gout (P< 0.05).Conclusion: There are many influencing factors of uric acid lowering drug treatment sensitivity in patients with primary gout. Hyperlipidemia is an independent risk factor with poor treatment sensitivity, which deserves more attention in clinic.
王雪娇, 李娟, 焦凌梅, 陈静, 陈玉雅, 符白玉, 李珑. 原发性痛风患者合并高脂血症对规律降尿酸药物治疗敏感性的影响[J]. 河北医学, 2022, 28(1): 107-111.
WANG Xuejiao, et al. Effect of Hyperlipidemia in Patients with Primary Gout on the Sensitivity of Regular Uric Acid Lowering Drugs. HeBei Med, 2022, 28(1): 107-111.
[1] 李志军.痛风及高尿酸血症的诊断与治疗[J].中华全科医学,2020,18(1):11~12. [2] Higashino T,Morimoto K,Nakaoka H,et al.Dysfunctional missense variant of OAT10/SLC22A13 decreases gout risk and serum uric acid levels[J].Annals of the Rheumatic Diseases:A Journal of Clinical Rheumatology and Connective Tissue Research,2020,79(1):164~166. [3] Hsu T W, Lee P S, Nfor O,et al.The interaction between sex and hyperlipidemia on gout risk is modulated by HLA-B polymorphic variants in adult taiwanese[J].Genes,2019,10(3):246~254. [4] Louthrenoo W, Jatuworapruk K, Lhakum P,et al.Performance of the 2015 American college of rheumatology/european league against rheumatism gout classification criteria in Thai patients[J].Rheumatology International,2017,37(5):705~711. [5] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中华健康管理学杂志,2017,11(1):7~28. [6] 杨丽华,刘晓丽,蒋雅琼,等.我国痛风的患病率及危险因素[J].医学研究杂志,2019,48(12):10~12,16. [7] Zhong Z, Huang Y, Huang X,et al.POS1144 Serum uric acid to creatinine ratio is associated with urinary uric acid excertion in patients with gout[J].Annals of the Rheumatic Diseases,2021,80(1):851~852. [8] Fatima T, Dehlin M, Turesson C,et al.The absolute risk of gout by clusters of gout-associated comorbidities and lifestyle factors-30 years follow-up of the malm preventive project[J].Arthritis Research & Therapy,2020,22(6):244~254. [9] 王蕾明、卢立芹、徐瑾.苯溴马隆治疗痛风伴高尿酸血症对患者肾功能的影响及血清BUA水平变化与预后的相关性分析[J].湖南师范大学学报(医学版),2020,17(4):115~118. [10] Albert J A, Hosey T, Lamoreaux B.Increased efficacy and tolerability of pegloticase in patients with uncontrolled gout co-treated with methotrexate:a retrospective study[J].Rheumatology and Therapy,2020,7(3):639~648. [11] Ray K K, Bakris G L, Banach M,et al.Effect of bempedoic acid on uric acid and gout in 3621 patients with hypercholesterolemia:pooled analyses from phase 3 trials[J].European Heart Journal,2020,41(2):357~364. [12] Lee Y H, Song G G.Uric acid level,gout and bone mineral density:a mendelian randomization study[J].European Journal of Clinical Investigation,2019,49(9):136~143.